graft versus host disease Archives
Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
Feb. 21, 2019—In 1906, English statistician Francis Galton happened to visit a livestock fair where fairgoers were invited to guess the dressed weight of an ox scheduled for imminent slaughter. Some 800 attendees took part and afterwards Galton got hold of the contest data.